TGFβ macrophage reprogramming: a new dimension of macrophage plasticity.

J Leukoc Biol

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN, 37232.

Published: February 2024

AI Article Synopsis

  • The August 2023 article in Science Signaling critiques the traditional macrophage classifications (M1/M2) by showing how transforming growth factor β (TGF-β) alters macrophage metabolism and function, leading to an unexpected phenotype.
  • TGF-β-treated macrophages increase glycolysis, decrease pro-inflammatory cytokines, and elevate coagulation factors, indicating a complex role in inflammation and metabolism during conditions like sepsis.
  • The study connects TGF-β's effects to COVID-19, showing similar metabolic changes in macrophages and suggesting that targeting TGF-β could be a therapeutic strategy for diseases characterized by uncontrolled inflammation and coagulation issues.

Article Abstract

The August 2023 article in Science Signaling, "TGF-β uncouples glycolysis and inflammation in macrophages and controls survival during sepsis," challenges the traditional M1/M2 macrophage classification by investigating the impact of transforming growth factor β on macrophage metabolism and function. Despite its conventional anti-inflammatory role, transforming growth factor β-treated macrophages exhibit a distinct phenotype marked by heightened glycolysis, suppressed proinflammatory cytokines, and increased coagulation factor expression. The study identifies phosphofructokinase, liver type as a crucial glycolytic enzyme regulated by transforming growth factor β via the mTOR-c-MYC pathway. Epigenetic changes induced by transforming growth factor β, such as increased Smad3 activation and reduced proinflammatory transcription factor motif enrichment, contribute to the anti-inflammatory profile. The research extends its implications to sepsis, revealing the role of transforming growth factor β in exacerbating coagulation and reducing survival in mouse models. This effect involves upregulation of coagulation factor F13A1, dependent on phosphofructokinase, liver type activity and glycolysis in macrophages. Connections to COVID-19 pathology are drawn, as transforming growth factor β-treated macrophages and SARS-CoV-2 E protein-exposed cells display similar metabolic profiles. Bioinformatic analysis of COVID-19 patient data suggests correlations between myeloid expression of TGFβR1, PFKL, and F13A1 with disease severity. The study challenges the M1/M2 classification, emphasizing the complexity of macrophage responses influenced by transforming growth factor β, proposing transforming growth factor β as a potential therapeutic target for conditions like sepsis and COVID-19 where dysregulated coagulation is significant. Overall, the research provides valuable insights into transforming growth factor β-mediated immunometabolic regulation, paving the way for future investigations and potential therapeutic interventions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11423798PMC
http://dx.doi.org/10.1093/jleuko/qiae001DOI Listing

Publication Analysis

Top Keywords

transforming growth
36
growth factor
36
factor
12
transforming
9
growth
9
role transforming
8
factor β-treated
8
β-treated macrophages
8
coagulation factor
8
phosphofructokinase liver
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!